Atrinsic (NASDAQ:PTIX) & Vanda Pharmaceuticals (NASDAQ:VNDA) Head-To-Head Review

Atrinsic (NASDAQ:PTIX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Volatility and Risk

Atrinsic has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Atrinsic and Vanda Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1	0	0	0	1.00
Vanda Pharmaceuticals	1	2	5	0	2.50

Vanda Pharmaceuticals has a consensus target price of $14.90, indicating a potential upside of 104.95%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Atrinsic.

Profitability

This table compares Atrinsic and Vanda Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Vanda Pharmaceuticals	-102.02%	-23.85%	-18.20%

Institutional and Insider Ownership

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Atrinsic and Vanda Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53 million	($3.45)	-0.17
Vanda Pharmaceuticals	$216.10 million	1.99	-$220.47 million	($3.73)	-1.95

Atrinsic has higher earnings, but lower revenue than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Summary

Vanda Pharmaceuticals beats Atrinsic on 8 of the 13 factors compared between the two stocks.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.